Altimmune (ALT)
Developing pemvidutide across MASH, AUD, and alcohol-associated liver disease.
Something off on this page? Send us feedback.
Built around pemvidutide, a glucagon/GLP-1 dual receptor agonist, with MASH as the lead program and AUD and ALD as active mid-stage indications. Operates as a single pre-revenue segment from Gaithersburg, Maryland, relying on clinical execution, regulatory alignment, and external capital before any product sales.
Centered on pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, with MASH as the lead indication and AUD and ALD as additional clinical programs. Legacy vaccine and HepTcell programs are not part of the current pipeline.
Operates from Gaithersburg, Maryland as a small, research-heavy team managed as a single segment. Execution now revolves around moving the MASH program into registrational development while maintaining the AUD and ALD studies.
Has not generated product sales, so the business depends on clinical readouts, FDA interactions, trial enrollment, and access to external financing. Competition spans liver-disease and incretin mechanisms from larger pharmaceutical companies and specialist biotech developers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 22, 2026 | Leerink Partners | Target | Target: — | Target: $10 |
| Apr 24, 2026 | Goldman Sachs | Target | Target: $20 | Target: $2.50 |
| Jan 27, 2026 | Barclays | Target | Target: — | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $326.3M · Total debt $35.7M · Total assets $527.2M · Shareholders' equity $474.2M
- Revenue
- $0
- Operating income
- −$26.2M
- Net income
- −$22.8M
No dividends on record.
| Institutions | 77.46% | 150.68M shares | |
|---|---|---|---|
| 222 holders · as of Jun 30, 2026 | |||
| Insiders | 0.40% | 781.1K shares | |
| 11 holders · as of Sep 17, 2026 | |||
| Strategic holders | 5.14% | 10.00M shares | |
| 1 holder · as of May 1, 2026 | |||
| Other | 17.00% | 33.06M shares | |
| remainder | |||
194.52M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.48% | 20.39M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 9.90% | 19.25M | as of Jun 30, 2026 |
State Street CorpInstitution | 6.22% | 12.10M | as of Jun 30, 2026 |
TCG Crossover Management, LLCInstitution | 5.14% | 10.00M | as of Jun 30, 2026 |
TCG Crossover GP II, LLCStrategic | 5.14% | 10.00M | filed May 1, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +15,000 | $2.95 |
| Apr 6, 2026 | John Gill | director | +9,200 | $3.41 |
| Apr 1, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +15,000 | $3.14 |
| Apr 1, 2026 | Gregory L. Weaver | officer: Chief Financial Officer | +10,000 | $3.15 |
| Mar 6, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +20,000 | $3.54 |
- Madrigal Pharmaceuticals
Approved MASH THR-beta benchmark with Rezdiffra
- Novo Nordisk (ADR)
Approved GLP-1 MASH entrant with broad metabolic scale
- Eli Lilly
Incretin challenger in MASH and obesity-linked liver disease
- Viking Therapeutics
Clinical THR-beta challenger with VK2809 MASH data
- GSK (ADR)
Hepatology pipeline overlap in MASH and ALD
- Alkermes
Approved AUD treatment benchmark through Vivitrol
- Inventiva (ADR)
Phase 3 oral pan-PPAR challenger in MASH
- Aligos Therapeutics
Early THR-beta MASH challenger with ALG-055009
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Altimmune | $3.38 | +3.21% | $635.9M | — | — | 20,513.9 | +820.0% |
| Madrigal Pharmaceuticals | $525.16 | +0.61% | $12.06B | — | — | 9.4 | +71.2% |
| Novo Nordisk (ADR) | $39.37 | −1.08% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Eli Lilly | $1,152.79 | −1.04% | $1.10T | 39.1 | 28.2 | 13.8 | +47.7% |
| Viking Therapeutics | $40.13 | +33.28% | $3.51B | — | — | — | — |
| GSK (ADR) | $50.55 | −1.05% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Alkermes | $44.10 | −0.18% | $7.41B | 115.4 | — | 4.4 | +27.0% |
| Inventiva (ADR) | $3.59 | −1.78% | $189.7M | — | — | 36.9 | −79.0% |
| Aligos Therapeutics | $5.56 | +1.28% | $34.0M | — | — | 1.1 | +2,778.6% |
| Median | 27.6 | 16.2 | 4.4 | +27.0% |